Analysts Set Expectations for electroCore FY2026 Earnings

Posted by Francis Steltz on Nov 10th, 2026

electroCore, Inc. (NASDAQ:ECOR – Free Report) – Analysts at Brookline Capital Markets lifted their FY2026 earnings estimates for shares of electroCore in a research report issued on Thursday, November 5th. Brookline Capital Markets analyst F. Ahmed now expects that the company will post earnings of ($1.25) per share for the year, up from their prior forecast of ($1.39). The consensus estimate for electroCore’s current full-year earnings is ($1.22) per share. Brookline Capital Markets also issued estimates for electroCore’s Q4 2026 earnings at ($0.23) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of electroCore in a research report on Monday, September 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, electroCore presently has a consensus rating of “Hold” and a consensus price target of $18.00.

View Our Latest Stock Report on ECOR

electroCore Stock Down 1.0%

Shares of electroCore stock opened at $7.18 on Tuesday. electroCore has a twelve month low of $4.41 and a twelve month high of $12.70. The stock has a market cap of $64.76 million, a price-to-earnings ratio of -5.17 and a beta of 1.23. The company’s fifty day moving average is $9.23 and its 200 day moving average is $7.76.

electroCore (NASDAQ:ECOR – Get Free Report) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.14. The business had revenue of $9.69 million for the quarter, compared to the consensus estimate of $10.93 million.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in electroCore stock. WealthShield Partners LLC bought a new stake in electroCore, Inc. (NASDAQ:ECOR – Free Report) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 25,978 shares of the company’s stock, valued at approximately $157,000. WealthShield Partners LLC owned 0.32% of electroCore at the end of the most recent reporting period. Hedge funds and other institutional investors own 26.74% of the company’s stock.

Insider Buying and Selling at electroCore

In related news, CFO Joshua S. Lev sold 3,000 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $9.36, for a total value of $28,080.00. Following the transaction, the chief financial officer owned 84,889 shares in the company, valued at $794,561.04. The trade was a 3.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Thomas Errico purchased 5,000 shares of the business’s stock in a transaction on Monday, September 14th. The shares were purchased at an average cost of $9.82 per share, for a total transaction of $49,100.00. Following the transaction, the director directly owned 363,904 shares of the company’s stock, valued at approximately $3,573,537.28. The trade was a 1.39% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have sold 20,000 shares of company stock valued at $200,120. 7.80% of the stock is currently owned by corporate insiders.

electroCore Company Profile

(Get Free Report)

electroCore, Inc (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components.

The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.